跳至主要内容
临床试验/ACTRN12613000032752
ACTRN12613000032752撤回4 期

Statin Therapy in Ischemia-Reperfusion Injury: A randomised trial to evaluate the effect of high dose rosuvastatin on myocardial infarct size post ST elevation myocardial infarction (STEMI).

SAHMRI0 个研究点目标入组 300 人开始时间: 2013年1月11日最近更新:
适应症

试验速览

阶段
4 期
状态
撤回
发起方
SAHMRI
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment

入排标准

年龄范围
18 Years 至 80 Years(—)
性别
All

入选标准

  • Symptoms of acute myocardial infarction within 12 hours with ST elevation of more than 1 mm in at least two contigous leads on ECG of new onset Left Bundle Branch Block.
  • Provision of written informed consent.

排除标准

  • Cardiogenic shock or symptomatic hypotension or sitting SBP < 95 mm Hg
  • Previous MI
  • Standard CMR contraindications (e.g. pacemaker, severe claustrophobia etc.)
  • Known serious or hypersensitivity reactions to statin
  • known familial hypercholesterolemia
  • known active liver disease or significant renal failure (eGFR < 45 mls/min)
  • Non-cardiac comorbidity with life expectation < 1 year.
  • Patients who are Filipino, Chinese, Japanese, Korean or Vietnamese.
  • Patients taking any of the following cyclosporine, gemfibrozel or fusidic acid.
  • Attending consultant intends to use high dose statin therapy, Atorvastatin 80 mgs or Rosuvastatin 40 mgs.

研究者

发起方
SAHMRI

相似试验

Statin Therapy in Ischemia-Reperfusion Injury... | 临床试验